Every material Form 8-K Edesa Biotech, Inc. has filed with the SEC since August 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edesa Biotech entered a Collaboration and License Agreement dated November 8, 2026, giving Kyorin Pharmaceutical exclusive rights to develop and sell paridiprubart for ARDS in Japan, while Edesa keeps rights elsewhere, including the United States, Europe and Canada. The deal provides a $12 million upfront payment, milestone payments and royalties, and Edesa also gave notice that it is terminating its at-the-market share sales agreement with H.C. Wainwright, effective November 16, 2026.
Kyorin pays a one-time, non-refundable upfront payment of $12 million
Development and regulatory milestones of up to $55 million, plus sales-based milestones of up to ¥12.0 billion
Kyorin pays tiered, low double-digit royalties on net sales in Japan
ATM agreement with H.C. Wainwright terminated effective November 16, 2026, with no termination penalties
On October 23, 2026, Edesa Biotech's board approved base salary increases for CEO Pardeep Nijhawan, President Michael Brooks and CFO Peter Weiler, effective retroactive to July 1, 2026. The filing says the executives' base salaries had last been adjusted in 2023. The filing does not state the total added cost, but the raises are a higher fixed compensation expense for shareholders to consider.
CEO Pardeep Nijhawan's base salary rises from $357,696 to $657,423.
President Michael Brooks's base salary rises from $335,340 to $591,681; CFO Peter Weiler's rises from $300,000 to $525,938.
Increases are retroactive to July 1, 2026; prior adjustments were made in 2023.
90% of Dr. Nijhawan's monthly base salary will continue to be paid in fully vested restricted share units under the 2019 Equity Incentive Compensation Plan.
Edesa Biotech reported that the FDA has cleared its Investigational New Drug application for a Phase 2 study of EB06 in vitiligo, allowing the company to expand patient recruitment to the United States. Patient recruitment is already underway in Canada, and the company anticipates topline data in the fourth quarter of 2027. The filing describes a clinical milestone, not a financial result, and the safety and efficacy of EB06 remain subject to clinical evaluation.
FDA cleared the IND application for the Phase 2 study of EB06 in vitiligo, announced October 15, 2026
Study will enroll up to 80 adults with moderate-to-severe nonsegmental vitiligo, randomized 1:1 to EB06 or placebo
First U.S. investigational sites are expected to begin enrolling subjects next quarter
Topline data anticipated in the fourth quarter of 2027
Edesa Biotech, Inc. priced an underwritten public offering of 3,870,500 common shares and pre-funded warrants for up to 675,000 common shares, each sold with a common share warrant, with gross proceeds expected to be approximately $25.0 million. The company expects net proceeds of approximately $23.1 million, to be used for general corporate purposes, and expects the offering to close on or about August 21, 2026, which adds new shares and warrants that can dilute existing shareholders.
Combined offering price of $5.50 per common share with a warrant, and $5.4999 per pre-funded warrant with a warrant.
Expected net proceeds of approximately $23.1 million; closing expected on or about August 21, 2026.
Warrants have a $7.50 exercise price and expire on the earlier of the 18-month anniversary of issuance or 30 days after public announcement of Phase 2 vitiligo topline data for EB06.
Underwriters hold a 30-day option to buy up to 681,825 additional shares; executive officers and directors agreed to a 90-day lock-up, subject to exceptions.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edesa Biotech, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →